Novel CHK1 inhibitor MU380 exhibits significant single-agent activity in TP53-mutated chronic lymphocytic leukemia cells

scientific article published on 11 April 2019

Novel CHK1 inhibitor MU380 exhibits significant single-agent activity in TP53-mutated chronic lymphocytic leukemia cells is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.3324/HAEMATOL.2018.203430
P932PMC publication ID6959166
P698PubMed publication ID30975914

P50authorMarek MrázQ60566897
P2093author name stringJiri Mayer
Marek Borsky
Martin Trbusek
Vaclav Seda
Yvona Brychtova
Karel Soucek
Alexandra Oltova
Josef Jaros
Kamil Paruch
Prashant Khirsariya
Miroslav Boudny
Jana Cerna
Zuzana Jaskova
Michaela Spunarova
Jan Verner
Jana Zemanova
Marie Kasparkova
Stanislav Drapela
P2860cites workTargeted disruption of the cell-cycle checkpoint gene ATR leads to early embryonic lethality in miceQ28143813
The ATR-p53 pathway is suppressed in noncycling normal and malignant lymphocytesQ28241779
B-cell receptor signalling and its crosstalk with other pathways in normal and malignant cellsQ28245018
The cancer therapeutic potential of Chk1 inhibitors: how mechanistic studies impact on clinical trial designQ28289090
Death by releasing the breaks: CHK1 inhibitors as cancer therapeuticsQ28298703
Aberrant cell cycle checkpoint function and early embryonic death in Chk1(-/-) miceQ28507011
Improving bioscience research reporting: the ARRIVE guidelines for reporting animal researchQ29547313
DNA damage response as a candidate anti-cancer barrier in early human tumorigenesisQ29614217
Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 databaseQ29616468
Direct in vivo evidence for increased proliferation of CLL cells in lymph nodes compared to bone marrow and peripheral bloodQ33774491
In vivo measurements document the dynamic cellular kinetics of chronic lymphocytic leukemia B cellsQ33830733
Chk1 inhibition as a novel therapeutic strategy for treating triple-negative breast and ovarian cancersQ34062570
Human lymphoid and myeloid cell development in NOD/LtSz-scid IL2R gamma null mice engrafted with mobilized human hemopoietic stem cellsQ34416761
The lymph node microenvironment promotes B-cell receptor signaling, NF-κB activation, and tumor proliferation in chronic lymphocytic leukemiaQ34542102
In vitro and in vivo model of a novel immunotherapy approach for chronic lymphocytic leukemia by anti-CD23 chimeric antigen receptorQ35001579
The fork and the kinase: a DNA replication tale from a CHK1 perspectiveQ35205026
G2 checkpoint abrogators as anticancer drugsQ35743997
Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic LeukemiaQ35903984
Cell cycle phase distribution analysis in chronic lymphocytic leukaemia: a significant number of cells reside in early G1-phaseQ36017262
In vitro and in vivo single-agent efficacy of checkpoint kinase inhibition in acute lymphoblastic leukemiaQ36255484
CHK1-targeted therapy to deplete DNA replication-stressed, p53-deficient, hyperdiploid colorectal cancer stem cellsQ36340540
BCL-2 as a therapeutic target in chronic lymphocytic leukemiaQ36343059
IGHV-unmutated and IGHV-mutated chronic lymphocytic leukemia cells produce activation-induced deaminase protein with a full range of biologic functionsQ36462397
The clinical development candidate CCT245737 is an orally active CHK1 inhibitor with preclinical activity in RAS mutant NSCLC and Eµ-MYC driven B-cell lymphomaQ36771796
Chk1 inhibition significantly potentiates activity of nucleoside analogs in TP53-mutated B-lymphoid cellsQ37641736
The Checkpoint Kinase 1 Inhibitor Prexasertib Induces Regression of Preclinical Models of Human NeuroblastomaQ38713227
Cancer-Specific Synthetic Lethality between ATR and CHK1 Kinase ActivitiesQ38805276
NOD/SCID IL2Rγ-null mouse xenograft model of human p53-mutated chronic lymphocytic leukemia and ATM-mutated mantle cell lymphoma using permanent cell linesQ38892495
Inhibition of the checkpoint kinase Chk1 induces DNA damage and cell death in human Leukemia and Lymphoma cellsQ38986400
Single-Agent Inhibition of Chk1 Is Antiproliferative in Human Cancer Cell Lines In Vitro and Inhibits Tumor Xenograft Growth In VivoQ39470410
Targeting the Replication Checkpoint Using SCH 900776, a Potent and Functionally Selective CHK1 Inhibitor Identified via High Content ScreeningQ39592286
Mutations driving CLL and their evolution in progression and relapseQ39714436
CHIR-124, a novel potent inhibitor of Chk1, potentiates the cytotoxicity of topoisomerase I poisons in vitro and in vivoQ40178792
Sustained signaling through the B-cell receptor induces Mcl-1 and promotes survival of chronic lymphocytic leukemia B cells.Q40455255
Reevaluation of ATR signaling in primary resting chronic lymphocytic leukemia cells: evidence for pro-survival or pro-apoptotic functionQ41344084
CHK1 Inhibition in Small-Cell Lung Cancer Produces Single-Agent Activity in Biomarker-Defined Disease Subsets and Combination Activity with Cisplatin or Olaparib.Q41466400
3R gene expression in chronic lymphocytic leukemia reveals insight into disease evolutionQ42042759
Mechanisms of action of a dual Cdc7/Cdk9 kinase inhibitor against quiescent and proliferating CLL cells.Q42808038
Drug-perturbation-based stratification of blood cancerQ47331796
Synthesis and Profiling of a Novel Potent Selective Inhibitor of CHK1 Kinase Possessing Unusual N-trifluoromethylpyrazole Pharmacophore Resistant to Metabolic N-dealkylationQ48014135
Checkpoint kinase 1 is essential for normal B cell development and lymphomagenesis.Q48250645
Single-agent ibrutinib in treatment-naïve and relapsed/refractory chronic lymphocytic leukemia: a 5-year experienceQ50044415
Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysisQ50054062
Bruton's tyrosine kinase inhibitors: first and second generation agents for patients with Chronic Lymphocytic Leukemia (CLL).Q50072188
ATR inhibition induces synthetic lethality and overcomes chemoresistance in TP53- or ATM-defective chronic lymphocytic leukemia cellsQ50913049
Endogenous Replication Stress Marks Melanomas Sensitive to CHEK1 Inhibitors In VivoQ52726809
Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trialQ53061290
Cell-cycle-dependent and ATM-independent expression of human Chk1 kinaseQ77954362
Evaluation of 230 patients with relapsed/refractory deletion 17p chronic lymphocytic leukaemia treated with ibrutinib from 3 clinical trialsQ89004911
P433issue12
P921main subjectchronic lymphocytic leukemiaQ1088156
P304page(s)2443-2455
P577publication date2019-04-11
P1433published inHaematologicaQ5638209
P1476titleNovel CHK1 inhibitor MU380 exhibits significant single-agent activity in TP53-mutated chronic lymphocytic leukemia cells
P478volume104